Esperanza Martín-Sánchez, Laura Blanco, Peter S Kim, Kamlesh Bisht, Hongfang Wang, Helgi Van de Velde, Tomas Jelinek, Catia Simoes, Felipe Prosper, Jesus F San Miguel, Ana Alfonso, Juan Bergua, Rebeca Rodríguez-Veiga, Susana Vives, David Martínez-Cuadrón, Pau Montesinos, Bruno Paiva, Aintzane Zabaleta
{"title":"在老年急性髓性白血病患者中使用伊沙妥昔单抗和 CD38/CD3xCD28 三特异性 T 细胞吸引器靶向 CD38。","authors":"Esperanza Martín-Sánchez, Laura Blanco, Peter S Kim, Kamlesh Bisht, Hongfang Wang, Helgi Van de Velde, Tomas Jelinek, Catia Simoes, Felipe Prosper, Jesus F San Miguel, Ana Alfonso, Juan Bergua, Rebeca Rodríguez-Veiga, Susana Vives, David Martínez-Cuadrón, Pau Montesinos, Bruno Paiva, Aintzane Zabaleta","doi":"10.1182/bloodadvances.2024013212","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":9228,"journal":{"name":"Blood advances","volume":null,"pages":null},"PeriodicalIF":7.4000,"publicationDate":"2024-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11321322/pdf/","citationCount":"0","resultStr":"{\"title\":\"Targeting CD38 with isatuximab and a novel CD38/CD3×CD28 trispecific T-cell engager in older patients with acute myeloid leukemia.\",\"authors\":\"Esperanza Martín-Sánchez, Laura Blanco, Peter S Kim, Kamlesh Bisht, Hongfang Wang, Helgi Van de Velde, Tomas Jelinek, Catia Simoes, Felipe Prosper, Jesus F San Miguel, Ana Alfonso, Juan Bergua, Rebeca Rodríguez-Veiga, Susana Vives, David Martínez-Cuadrón, Pau Montesinos, Bruno Paiva, Aintzane Zabaleta\",\"doi\":\"10.1182/bloodadvances.2024013212\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":9228,\"journal\":{\"name\":\"Blood advances\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":7.4000,\"publicationDate\":\"2024-08-13\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11321322/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Blood advances\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1182/bloodadvances.2024013212\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"HEMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Blood advances","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1182/bloodadvances.2024013212","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"HEMATOLOGY","Score":null,"Total":0}
期刊介绍:
Blood Advances, a semimonthly medical journal published by the American Society of Hematology, marks the first addition to the Blood family in 70 years. This peer-reviewed, online-only, open-access journal was launched under the leadership of founding editor-in-chief Robert Negrin, MD, from Stanford University Medical Center in Stanford, CA, with its inaugural issue released on November 29, 2016.
Blood Advances serves as an international platform for original articles detailing basic laboratory, translational, and clinical investigations in hematology. The journal comprehensively covers all aspects of hematology, including disorders of leukocytes (both benign and malignant), erythrocytes, platelets, hemostatic mechanisms, vascular biology, immunology, and hematologic oncology. Each article undergoes a rigorous peer-review process, with selection based on the originality of the findings, the high quality of the work presented, and the clarity of the presentation.